Preclinical studies of an antibody-based drug for the treatment of coronavirus have already been completed. This was announced on Friday, February 5, during a press conference by the Vice President of the Russian Academy of Sciences (RAS) Vladimir Chekhonin.
He noted that a series of organic clinical trials are currently being prepared.
According to Chekhonin, a drug for COVID-19 based on neutralizing antibodies can completely block the virus, especially in the early stages of the development of the disease.
“In Russia, similar work is carried out at different sites, the most advanced is the experience of the Institute of Bioorganic Chemistry named after. Ovchinnikov and Shemyakin under the leadership of Alexander Gabibov “, – said the vice-president of the Russian Academy of Sciences.
At the end of 2020, the head of the Gamaleya Center, Alexander Gintsburg, announced that it is planned to start testing a drug for the treatment of coronavirus based on antibodies in humans in the fall of 2021.
According to him, several antibody-based drugs for the treatment of coronavirus may appear in Russia. At the same time, it is expected that such drugs will be several times more expensive than a vaccine.
On December 21, Russian Health Minister Mikhail Murashko announced on December 21 that more than 10 drugs for the treatment of coronavirus have already been registered in the country.
Up-to-date information on the situation with coronavirus is available on the websites of stopcoronavirus.rf and access vsem.rf, as well as by the hashtag #WeVotre. Hotline phone: 8 (800) 2000-112.